These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28937974)

  • 21. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoantigen landscape dynamics during human melanoma-T cell interactions.
    Verdegaal EM; de Miranda NF; Visser M; Harryvan T; van Buuren MM; Andersen RS; Hadrup SR; van der Minne CE; Schotte R; Spits H; Haanen JB; Kapiteijn EH; Schumacher TN; van der Burg SH
    Nature; 2016 Aug; 536(7614):91-5. PubMed ID: 27350335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoantigens encoded in the cancer genome.
    Schumacher TN; Hacohen N
    Curr Opin Immunol; 2016 Aug; 41():98-103. PubMed ID: 27518850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
    Qin Y; Lu J; Bao L; Zhu H; Li J; Li L; Lai Y; Shi H; Wang Y; Liu Y; Jiang B; Huang X
    Chin Med J (Engl); 2014; 127(9):1666-71. PubMed ID: 24791872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline.
    Schenck RO; Lakatos E; Gatenbee C; Graham TA; Anderson ARA
    BMC Bioinformatics; 2019 May; 20(1):264. PubMed ID: 31117948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
    Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
    Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
    Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
    Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.
    Qin Y; Ekmekcioglu S; Forget MA; Szekvolgyi L; Hwu P; Grimm EA; Jazaeri AA; Roszik J
    Front Immunol; 2017; 8():689. PubMed ID: 28670312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy.
    Mauriello A; Zeuli R; Cavalluzzo B; Petrizzo A; Tornesello ML; Buonaguro FM; Ceccarelli M; Tagliamonte M; Buonaguro L
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival.
    Li W; Amei A; Bui F; Norouzifar S; Lu L; Wang Z
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment.
    Brancati VU; Minutoli L; Marini HR; Puzzolo D; Allegra A
    Curr Oncol; 2023 Apr; 30(5):4603-4617. PubMed ID: 37232806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
    Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
    Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
    Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
    Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.